Avoro Capital Advisors LLC Has $1.02 Billion Stock Holdings in Ascendis Pharma A/S $ASND

Key Points

• Avoro Capital Advisors increased its stake to 5,110,000 shares (adding 130,000 in Q3), valuing its position at about $1.02 billion and representing roughly 8.28% ownership of Ascendis—the firm’s largest holding (≈13.1% of Avoro’s portfolio).
• Analyst sentiment is broadly positive with a consensus rating of "Moderate Buy" and an average price target of $289.88, while several firms have recently raised targets (Evercore $324, RBC $275, Wedbush $273, Morgan Stanley $256).
• Recent results showed a sizable EPS miss (reported -$0.64 vs. -$0.06 expected) while revenue modestly beat at $290.4 million; the company has a market cap of $14.01 billion and a negative P/E.

Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,110,000 shares of the biotechnology company's stock after purchasing an additional 130,000 shares during the quarter. Ascendis Pharma A/S comprises about 13.1% of Avoro Capital Advisors LLC's investment portfolio, making the stock its biggest position. Avoro Capital Advisors LLC owned about 8.28% of Ascendis Pharma A/S worth $1,015,919,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Jones Financial Companies Lllp increased its stake in Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 83 shares during the period. Quadrant Capital Group LLC purchased a new position in Ascendis Pharma A/S during the 3rd quarter valued at about $74,000. Farther Finance Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 115.3% during the third quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company's stock valued at $95,000 after purchasing an additional 256 shares in the last quarter. Toth Financial Advisory Corp increased its holdings in Ascendis Pharma A/S by 33.7% during the third quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company's stock valued at $118,000 after buying an additional 150 shares during the period. Finally, GAMMA Investing LLC raised its stake in Ascendis Pharma A/S by 15.2% in the third quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company's stock worth $146,000 after buying an additional 97 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Evercore reissued an "outperform" rating and issued a $324.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Wedbush lifted their target price on Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an "outperform" rating in a research note on Thursday, February 12th. Royal Bank Of Canada boosted their target price on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an "outperform" rating in a report on Monday, March 2nd. Morgan Stanley reissued an "overweight" rating and set a $256.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, February 12th. Finally, Wall Street Zen lowered shares of Ascendis Pharma A/S from a "buy" rating to a "hold" rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $289.88.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $225.98 on Friday. The firm has a 50-day simple moving average of $224.24 and a two-hundred day simple moving average of $211.10. Ascendis Pharma A/S has a fifty-two week low of $124.06 and a fifty-two week high of $248.60. The company has a market cap of $14.01 billion, a P/E ratio of -51.36 and a beta of 0.43.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The company had revenue of $290.38 million during the quarter, compared to analysts' expectations of $285.35 million. Equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.